News & Media

Keep up with our progress

Media and others looking to learn more about our latest news can reach us at media@rycarma.com.

Filter Posts by Categories:

RyCarma Therapeutics Appoints Elizabeth Tarka, M.D., as Chief Medical Officer

Press Release
Read More

RyCarma Therapeutics Announces New Leadership and Company Name, Introduces Program in Heart Failure

Press Release
Read More

Forbion-backed cardio biotech rebrands to RyCarma with Phase 2 plans

In the News
Read More

Structural basis for ryanodine receptor type 2 leak in heart failure and arrhythmogenic disorders

Publication
Read More

ARMGO Pharma Publishes Positive Phase 1b Trial Results of Rycal® ARM210 for the Treatment of Ryanodine Receptor 1 Related Myopathies

Press Release
Read More

Rycal S48168 (ARM210) for RYR1-related myopathies: a phase one, open-label, dose-escalation trial

Publication
Read More

Targeting ryanodine receptors to treat human diseases

Publication
Read More

A drug and ATP binding site in type 1 ryanodine receptor

Publication
Read More

Structural analyses of human ryanodine receptor type 2 channels reveal the mechanisms for sudden cardiac death and treatment

Publication
Read More

ARMGO Pharma raises $35 million to progress clinical studies of lead molecule ARM210 in cardiac and skeletal muscle diseases

Press Release
Read More

Intracellular calcium leak in heart failure and atrial fibrillation: a unifying mechanism and therapeutic target

Publication
Read More

Intracellular calcium leak as a therapeutic target for RYR1-related myopathies

Publication
Read More

Calcium cycling proteins and heart failure: mechanisms and therapeutics

Publication
Read More
Back to top